News

As per terms of the deal, Genentech will use Lodo Therapeutics’ genome mining and biosynthetic cluster assembly platform to discover novel molecules with therapeutic potential against multiple disease-related targets.

Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), Escient will initially pursue therapies for neuro-immuno-inflammatory and autoreactive

DUBs are a family of over a hundred proteases that play important roles in protein and cellular homeostasis, processes that are critical to normal cell function. Evidence suggests

The specialty pharmaceutical company had submitted a new drug application, seeking approval for Tlando as TRT for adult males with conditions caused by deficiency of endogenous testosterone (hypogonadism). Lipocine

The approval has been granted for Lynparza (olaparib) tablets (300mg twice daily) to be used as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian

For over a decade, fewer than 10% of clinical trials that enter Phase I achieve FDA approval. Too many new drug submissions receive a rejection letter, request for

The label update is effective immediately and based on results from the Phase 4 TOURMALINE study, which showed no statistically significant difference between the groups taking Veltassa with

As per the terms of the deal, the Japanese pharma company will pay $30.33 in cash for each Shire share along with either 0.839 new Takeda shares or

The deal gives Luye the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand,